205 related articles for article (PubMed ID: 36854172)
41. Copper-free click-chemistry platform to functionalize cisplatin prodrugs.
Pathak RK; McNitt CD; Popik VV; Dhar S
Chemistry; 2014 Jun; 20(23):6861-5. PubMed ID: 24756923
[TBL] [Abstract][Full Text] [Related]
42. Computational Exploration of the Synergistic Anticancer Effect of a Multi-Action Ru(II)-Pt(IV) Conjugate.
Scoditti S; Mazzone G; Sanna N; Sicilia E
Inorg Chem; 2022 Aug; 61(32):12903-12912. PubMed ID: 35900874
[TBL] [Abstract][Full Text] [Related]
43. Endowing Pt(IV) with Perfluorocarbon Chains and Human Serum Albumin Encapsulation for Highly Effective Antitumor Chemoimmunotherapy.
Xie P; Jin Q; Zhang L; Zhang H; Montesdeoca N; Karges J; Xiao H; Mao X; Song H; Shang K
ACS Nano; 2024 May; 18(21):13683-13695. PubMed ID: 38749906
[TBL] [Abstract][Full Text] [Related]
44. Flavin-Conjugated Pt(IV) Anticancer Agents.
Sánchez-Camacho J; Infante-Tadeo S; Carrasco AC; Scoditti S; Martínez Á; Barroso-Bujans F; Sicilia E; Pizarro AM; Salassa L
Inorg Chem; 2023 Apr; 62(14):5644-5651. PubMed ID: 36990656
[TBL] [Abstract][Full Text] [Related]
45. Platinum(IV) prodrug conjugated Pd@Au nanoplates for chemotherapy and photothermal therapy.
Shi S; Chen X; Wei J; Huang Y; Weng J; Zheng N
Nanoscale; 2016 Mar; 8(10):5706-13. PubMed ID: 26900670
[TBL] [Abstract][Full Text] [Related]
46. Multiaction Pt(IV) Prodrugs Releasing Cisplatin and Dasatinib Are Potent Anticancer and Anti-Invasive Agents Displaying Synergism between the Two Drugs.
Markova L; Maji M; Kostrhunova H; Novohradsky V; Kasparkova J; Gibson D; Brabec V
J Med Chem; 2024 Jun; 67(11):9745-9758. PubMed ID: 38819023
[TBL] [Abstract][Full Text] [Related]
47. Hybrid inorganic (nonporous silica)/organic (alginate) core-shell platform for targeting a cisplatin-based Pt(IV) anticancer prodrug.
Ravera M; Gabano E; Bonzani D; Zanellato I; Arrais A; Cantamessa S; Biggiogera M; Osella D
J Inorg Biochem; 2018 Dec; 189():185-191. PubMed ID: 30312905
[TBL] [Abstract][Full Text] [Related]
48. A red-light activatable and mitochondrion-targeting Pt
Li Y; Wang Z; Qi Y; Tang Z; Li X; Huang Y
Chem Commun (Camb); 2022 Jul; 58(60):8404-8407. PubMed ID: 35796077
[TBL] [Abstract][Full Text] [Related]
49. Multi-action Pt(IV) anticancer agents; do we understand how they work?
Gibson D
J Inorg Biochem; 2019 Feb; 191():77-84. PubMed ID: 30471522
[TBL] [Abstract][Full Text] [Related]
50. Expanding the Arsenal of Pt
Yempala T; Babu T; Karmakar S; Nemirovski A; Ishan M; Gandin V; Gibson D
Angew Chem Int Ed Engl; 2019 Dec; 58(50):18218-18223. PubMed ID: 31599054
[TBL] [Abstract][Full Text] [Related]
51. Platinum(IV)-Estramustine Multiaction Prodrugs Are Effective Antiproliferative Agents against Prostate Cancer Cells.
Karmakar S; Kostrhunova H; Ctvrtlikova T; Novohradsky V; Gibson D; Brabec V
J Med Chem; 2020 Nov; 63(22):13861-13877. PubMed ID: 33175515
[TBL] [Abstract][Full Text] [Related]
52. Nano-assembly of ursolic acid with platinum prodrug overcomes multiple deactivation pathways in platinum-resistant ovarian cancer.
Wang Y; Luo Z; Zhou D; Wang X; Chen J; Gong S; Yu Z
Biomater Sci; 2021 Jun; 9(11):4110-4119. PubMed ID: 33949442
[TBL] [Abstract][Full Text] [Related]
53. Biotinylated Pt(IV) prodrugs with elevated lipophilicity and cytotoxicity.
Spector D; Erofeev A; Gorelkin P; Skvortsov D; Trigub A; Markova A; Nikitina V; Ul'yanovskiy N; Shtil' A; Semkina A; Vlasova K; Zyk N; Majouga A; Beloglazkina E; Krasnovskaya O
Dalton Trans; 2023 Jan; 52(4):866-871. PubMed ID: 36629146
[TBL] [Abstract][Full Text] [Related]
54. Activation of Platinum(IV) Prodrugs By Motexafin Gadolinium as a Redox Mediator.
Thiabaud G; McCall R; He G; Arambula JF; Siddik ZH; Sessler JL
Angew Chem Int Ed Engl; 2016 Oct; 55(41):12626-31. PubMed ID: 27377046
[TBL] [Abstract][Full Text] [Related]
55. Single-Cell Chemistry of Photoactivatable Platinum Anticancer Complexes.
Bolitho EM; Sanchez-Cano C; Shi H; Quinn PD; Harkiolaki M; Imberti C; Sadler PJ
J Am Chem Soc; 2021 Dec; 143(48):20224-20240. PubMed ID: 34808054
[TBL] [Abstract][Full Text] [Related]
56. Emerging platinum(iv) prodrugs to combat cisplatin resistance: from isolated cancer cells to tumor microenvironment.
Wang Z; Deng Z; Zhu G
Dalton Trans; 2019 Feb; 48(8):2536-2544. PubMed ID: 30633263
[TBL] [Abstract][Full Text] [Related]
57. Interactions between mitochondria-damaging platinum(IV) prodrugs and cytochrome c.
Jayawardhana AMDS; Zheng YR
Dalton Trans; 2022 Feb; 51(5):2012-2018. PubMed ID: 35029256
[TBL] [Abstract][Full Text] [Related]
58. Pt(IV) pro-drugs with an axial HDAC inhibitor demonstrate multimodal mechanisms involving DNA damage and apoptosis independent of cisplatin resistance in A2780/A2780cis cells.
Almotairy ARZ; Montagner D; Morrison L; Devereux M; Howe O; Erxleben A
J Inorg Biochem; 2020 Sep; 210():111125. PubMed ID: 32521289
[TBL] [Abstract][Full Text] [Related]
59. Enhanced potency of a chloro-substituted polyaromatic platinum(II) complex and its platinum(IV) prodrug against lung cancer.
Baz J; Khoury A; Elias MG; Mansour N; Mehanna S; Hammoud O; Gordon CP; Taleb RI; Aldrich-Wright JR; Daher CF
Chem Biol Interact; 2024 Jan; 388():110834. PubMed ID: 38103879
[TBL] [Abstract][Full Text] [Related]
60. Mitochondria-targeted Pt(IV) prodrugs conjugated with an aggregation-induced emission luminogen against breast cancer cells by dual modulation of apoptosis and autophagy inhibition.
Su Y; Tu Y; Lin H; Wang MM; Zhang GD; Yang J; Liu HK; Su Z
J Inorg Biochem; 2022 Jan; 226():111653. PubMed ID: 34740039
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
